Forest Ray PhD,  —

People with Parkinson’s disease who are hospitalized with COVID-19 may have a greater risk for more severe infections and higher mortality, according to a recent study of German hospital records. The study, “Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson’s Disease in Germany,” was published…

Nitrogen dioxide (NO2) is associated significantly with a higher risk for developing Parkinson’s disease, according to a recent study from Korea. The finding reinforces previous research showing a potential link between air pollution and Parkinson’s. The results also prompted researchers to suggest that better air pollution regulations might lower…

The U.S. Food and Drug Administration (FDA) has approved PharmaTher‘s investigational new drug (IND) application for ketamine as a treatment for levodopa-induced dyskinesia in people with Parkinson’s disease. The approval clears the way for PharmaTher to proceed with a Phase 2 clinical trial to study low-dose ketamine —…

Anxiety appears to worsen the physical and cognitive symptoms of Parkinson’s disease, despite the various ways that individuals experience it, according to a recent study. Researchers and healthcare professionals, the study concluded, should take these personal experiences into account when crafting both individual therapies and future research. The study,…

Alligator Bioscience and BioArctic AB have partnered to research and develop new therapies for neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s. “We are very pleased that BioArctic has recognized the power of Alligator’s proprietary phage display libraries which have been successfully used to generate Alligator’s…

Centogene announced plans to recruit 2,500 more patients this year into its observational Rostock International Parkinson’s Disease (ROPAD) study of how genetic factors contribute to the development of Parkinson’s. “We recently reached a significant study milestone, but this is just the beginning,” Peter Bauer, MD, Centogene’s chief genomic…

A new research training program called NeuroInsight is seeking to teach scientists in the data analytics and neuroscience skills needed to research Parkinson’s disease and other neurological conditions. The program received a €4.7 million ($5.64 million) grant from the Marie Skłodowska-Curie Actions COFUND, a European fund that provides financial…

Disruptions in a network of interconnected nerves in the brain appear to underlie what are known as perception hallucinations in people with Parkinson’s disease, according to a recent study. This finding — taken from robotic-guided movements that act as a type of “brain stress test” — supports this network as a…

The personality trait neuroticism correlates with a higher risk of developing Parkinson’s disease, according to recent research. The study, “Neuroticism and Risk of Parkinson’s Disease: A Meta-Analysis,” was published in the journal Movement Disorders. Neuroticism refers to an individual’s tendency to experience negative emotions, self-consciousness, vulnerability…

A newly opened Phase 2 clinical trial is evaluating adult stem cells as a potentially disease-modifying treatment for Parkinson’s, building on an earlier study, thought to be the first of its kind, that found a single infusion of these cells safe and well tolerated by patients. This study will use…